These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12269847)

  • 1. The clinical value of erythropoietin in patients with cancer.
    Dührsen U
    Drugs; 2002; 62(14):2013-23. PubMed ID: 12269847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin: can we afford to use it? Can we afford not to?
    Laird J
    Transfus Med; 2006 Jun; 16(3):204-5. PubMed ID: 16764600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of erythropoietin in the treatment of lung cancer associated anaemia.
    Scagliotti GV; Novello S
    Lung Cancer; 2001 Dec; 34 Suppl 4():S91-4. PubMed ID: 11742710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods.
    Ossa DF; Briggs A; McIntosh E; Cowell W; Littlewood T; Sculpher M
    Pharmacoeconomics; 2007; 25(3):223-37. PubMed ID: 17335308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management options for cancer therapy-related anaemia.
    Littlewood TJ
    Drug Saf; 2002; 25(7):525-35. PubMed ID: 12093310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.
    Beguin Y
    Drug Saf; 1998 Oct; 19(4):269-82. PubMed ID: 9804442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
    Cheer SM; Wagstaff AJ
    Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel uses for recombinant erythropoietin therapy in unlicensed indications.
    Macartney CA; Adgey AA; Jones FG; Morris TC; McMullin MF
    Hematol J; 2004; 5(2):181-5. PubMed ID: 15048070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
    Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):459-72. PubMed ID: 10662393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of human recombinant erythropoietin in oncologic surgery].
    Mercuriali F
    Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of erythropoietin in cancer-related anaemia: a double-edged sword?
    Guan X; Chen L
    J Int Med Res; 2008; 36(1):1-8. PubMed ID: 18230261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Zealand cancer patients should have access to erythropoietin treatment.
    Carter J; Clay J
    N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.